神経遺伝学的検査市場の2030年までの予測：タイプ別、エンドユーザー別、地域別の世界分析

Stratistics MRCによると、神経遺伝学的検査の世界市場は、2023年に6億1,670万米ドルを占め、予測期間中に12.1％のCAGRで成長し、2030年までに13億7,210万米ドルに達すると予想されています。

神経遺伝学的検査は、神経学的状態に関連する特定の遺伝的変異を特定するために、個人の遺伝的構成を調べることを含みます。その用途には、神経疾患の診断、危険因子の評価、個別化された治療計画の指導が含まれ、より的を絞った効果的なヘルスケア介入につながります。

WHOの報告書によると、欧州地域は神経疾患の世界的負担の11.2%を占めており、次いで西太平洋地域が10%を占めています。

神経疾患の有病率の上昇

アルツハイマー病、パーキンソン病、様々な神経発達障害のような疾患に対する認識と理解の高まりは、正確で早期の遺伝子検査に対する需要の高まりを促しています。神経遺伝学的検査の進歩は、これらの疾患の遺伝的素因や危険因子を知る窓を提供し、早期診断と的確な治療計画を容易にします。これらの疾患が注目され、医学的理解が進むにつれて、効果的な神経遺伝学的検査の必要性は、介入を調整し、より良い管理を可能にし、これらの課題である神経疾患の発症や進行を回避または遅延させる可能性において極めて重要になります。

検査に伴う高額な費用と限られたアクセシビリティ

遺伝子検査法の複雑な性質は、専門的な機器や専門知識の必要性と相まって、検査費用の高騰の一因となり、これらのサービスを多くの個人にとって手の届かないものにしています。さらに、特に恵まれない地域や遠隔地では、高度な神経遺伝学的検査へのアクセスが限られているため、これらの重要な診断ツールの利用が制限されています。その結果、最先端ヘルスケアソリューションへのアクセスにおける格差が依然として存在し、多くの人々が神経疾患の早期診断、個別化治療、リスク評価の恩恵を受けることができないです。

研究開発の進展

遺伝子検査技術の継続的な進歩は、神経疾患の遺伝的基盤に対する深い洞察と相まって、より洗練された、正確で包括的な検査法の開発を後押ししています。この進歩は、遺伝子検査が可能な疾患の範囲を広げるだけでなく、診断の精度と信頼性を高める。さらに、新規の遺伝子マーカーや潜在的な治療標的の発見を促し、神経学における個別化医療の進化を促進しています。

遺伝子検査法の複雑さ

遺伝子検査技術は、シークエンシング、マイクロアレイ解析、遺伝子変異の解釈といった複雑なプロセスを伴うことが多く、その実施と理解は困難です。高度に専門化された機器、熟練した専門家、広範なバイオインフォマティクス解析が必要なため、運用コストが高くなり、高度な検査へのアクセスが制限される可能性があります。さらに、これらの検査の複雑な性質は、エラー、データの誤った解釈、あるいは誤診を引き起こし、その信頼性と精度に影響を与える可能性があります。さらに、遺伝子検査の複雑さは、特に技術インフラやヘルスケアの専門知識に乏しい地域では、医療提供者や患者がこうした診断ツールを受け入れることを躊躇させる可能性があります。

COVID-19の影響：

COVID-19の大流行は市場に大きな影響を与え、課題と機会の両方をもたらしました。サプライチェーンや臨床業務における初期の混乱は検査へのアクセスに影響を与えたが、ウイルスの神経学的影響を理解する緊急性が神経遺伝学の研究開発を加速させました。遠隔医療と遠隔検査が脚光を浴び、患者へのアクセスと診断が容易になっています。この時期、神経疾患における遺伝子検査の重要性が強調され、検査技術への投資と技術革新が促進されました。当初の挫折にもかかわらず、パンデミックは進歩に拍車をかけ、ヘルスケアにおいて神経遺伝学的検査が果たす重要な役割がより広く認識されるようになり、市場の将来の展望を再構築する可能性が出てきました。

予測期間中、ポリメラーゼ連鎖反応（PCR）検査分野が最大となる見込み

ポリメラーゼ連鎖反応（PCR）検査は市場で大きなシェアを占めています。PCRのDNAセグメントを増幅する能力は、ハンチントン病やパーキンソン病のような疾患に関連する変異を検出するのに役立ちます。その高い特異性と感度は、遺伝子マーカーの正確な分析に力を与え、早期診断と疾患モニタリングに極めて重要です。PCRの役割は神経学における研究、医薬品開発、個別化医療にまで及び、疾患の遺伝的基盤の理解における進歩を促進します。基礎的なツールとして、PCR検査は神経遺伝学的検査に革命を起こし続け、研究と臨床アプローチの両方を形作る洞察を育みます。

予測期間中、病院セグメントが最もCAGRが高いと予測されます。

予測期間中、市場内で最もCAGRが高いのは病院です。病院は高度な検査施設へのアクセスを提供し、包括的な遺伝子スクリーニングを可能にし、神経遺伝性疾患の同定を支援します。これらの機関は、検査を診断経路に統合し、疾患の早期発見と個別化治療戦略を促進しています。病院はまた、遺伝学者、神経学者、その他の専門家を集めて総合的なケアを提供し、進行中の研究に貢献し、最先端の検査手法を導入することで、神経遺伝学的検査の展望を大きく形作る、学際的な協力の拠点としての役割も果たしています。

最大のシェアを占める地域：

北米は重要な位置を占めており、予測期間中最大のシェアを占めると予想されます。この地域には大手バイオテクノロジー企業や製薬企業があり、技術革新を促進し、最先端の検査手法の開発を推進しています。神経疾患の有病率が高く、ヘルスケアシステムが積極的な北米では、臨床および研究領域で神経遺伝学的検査が幅広く採用されています。この地域の市場は、強力な規制の枠組み、学術機関と産業界の戦略的協力関係、個別化医療への重点の高まりによって特徴付けられ、北米が神経遺伝学的検査の進歩の最前線における地位を固めています。

CAGRが最も高い地域：

アジア太平洋地域は、市場で最も高いCAGRを記録しました。この地域は人口が多く多様性に富んでいるため、神経疾患の負担が大きく、高度な診断ソリューションの必要性が高まっています。さらに、新興経済国の存在と政府の支援策により、産業界と研究機関の連携が促進され、検査へのアクセスが拡大し、アジア太平洋地域における神経疾患の診断と管理のためのテーラーメイドアプローチの進化に拍車がかかっています。

無料のカスタマイズサービス：

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

• 企業プロファイル
  • 追加市場プレイヤーの包括的プロファイリング（3社まで）
  • 主要企業のSWOT分析（3社まで）
• 地域セグメンテーション
  • 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
• 競合ベンチマーキング
  • 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

目次

第1章 エグゼクティブサマリー

第2章 序文

• 概要
• ステークホルダー
• 調査範囲
• 調査手法
  • データマイニング
  • データ分析
  • データ検証
  • 調査アプローチ
• 調査ソース
  • 1次調査ソース
  • 2次調査ソース
  • 前提条件

第3章 市場動向分析

• 促進要因
• 抑制要因
• 機会
• 脅威
• エンドユーザー分析
• 新興市場
• 新型コロナウイルス感染症（COVID-19）の影響

第4章 ポーターのファイブフォース分析

• 供給企業の交渉力
• 買い手の交渉力
• 代替品の脅威
• 新規参入業者の脅威
• 競争企業間の敵対関係

第5章 世界の神経遺伝学的検査市場：タイプ別

• マイクロアレイ解析
• 全エクソームシークエンシング（WES）
• マルチプレックスライゲーション依存プローブ増幅（MLPA）
• ポリメラーゼ連鎖反応（PCR）検査
• その他のタイプ

第6章 世界の神経遺伝学的検査市場：エンドユーザー別

• 病院
• 専門クリニック
• 研究機関
• 診断研究所
• その他のエンドユーザー

第7章 世界の神経遺伝学的検査市場：地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン
  • その他の欧州
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • ニュージーランド
  • 韓国
  • その他のアジア太平洋
• 南米
  • アルゼンチン
  • ブラジル
  • チリ
  • その他の南米
• 中東・アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • カタール
  • 南アフリカ
  • その他の中東・アフリカ

第8章 主な発展

• 契約、パートナーシップ、コラボレーション、合弁事業
• 買収と合併
• 新製品の発売
• 事業拡大
• その他の主要戦略

第9章 企業プロファイル

• Invitae Corporation
• Ambry Genetics
• PerkinElmer
• GeneDx
• Centogene
• Blueprint Genetics
• Genomic Health（Exact Sciences）
• Fulgent Genetics
• QIAGEN
• Baylor Genetics

List of Tables

• Table 1 Global Neurogenetic Testing Market Outlook, By Region (2021-2030) ($MN)
• Table 2 Global Neurogenetic Testing Market Outlook, By Type (2021-2030) ($MN)
• Table 3 Global Neurogenetic Testing Market Outlook, By Microarray Analysis (2021-2030) ($MN)
• Table 4 Global Neurogenetic Testing Market Outlook, By Whole-Exome Sequencing (WES) (2021-2030) ($MN)
• Table 5 Global Neurogenetic Testing Market Outlook, By Multiplex Ligation Dependent Probe Amplification (MLPA) (2021-2030) ($MN)
• Table 6 Global Neurogenetic Testing Market Outlook, By Polymerase Chain Reaction (PCR) Tests (2021-2030) ($MN)
• Table 7 Global Neurogenetic Testing Market Outlook, By Other Types (2021-2030) ($MN)
• Table 8 Global Neurogenetic Testing Market Outlook, By End User (2021-2030) ($MN)
• Table 9 Global Neurogenetic Testing Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 10 Global Neurogenetic Testing Market Outlook, By Specialty Clinics (2021-2030) ($MN)
• Table 11 Global Neurogenetic Testing Market Outlook, By Research Institutes (2021-2030) ($MN)
• Table 12 Global Neurogenetic Testing Market Outlook, By Diagnostics Laboratories (2021-2030) ($MN)
• Table 13 Global Neurogenetic Testing Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 14 North America Neurogenetic Testing Market Outlook, By Country (2021-2030) ($MN)
• Table 15 North America Neurogenetic Testing Market Outlook, By Type (2021-2030) ($MN)
• Table 16 North America Neurogenetic Testing Market Outlook, By Microarray Analysis (2021-2030) ($MN)
• Table 17 North America Neurogenetic Testing Market Outlook, By Whole-Exome Sequencing (WES) (2021-2030) ($MN)
• Table 18 North America Neurogenetic Testing Market Outlook, By Multiplex Ligation Dependent Probe Amplification (MLPA) (2021-2030) ($MN)
• Table 19 North America Neurogenetic Testing Market Outlook, By Polymerase Chain Reaction (PCR) Tests (2021-2030) ($MN)
• Table 20 North America Neurogenetic Testing Market Outlook, By Other Types (2021-2030) ($MN)
• Table 21 North America Neurogenetic Testing Market Outlook, By End User (2021-2030) ($MN)
• Table 22 North America Neurogenetic Testing Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 23 North America Neurogenetic Testing Market Outlook, By Specialty Clinics (2021-2030) ($MN)
• Table 24 North America Neurogenetic Testing Market Outlook, By Research Institutes (2021-2030) ($MN)
• Table 25 North America Neurogenetic Testing Market Outlook, By Diagnostics Laboratories (2021-2030) ($MN)
• Table 26 North America Neurogenetic Testing Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 27 Europe Neurogenetic Testing Market Outlook, By Country (2021-2030) ($MN)
• Table 28 Europe Neurogenetic Testing Market Outlook, By Type (2021-2030) ($MN)
• Table 29 Europe Neurogenetic Testing Market Outlook, By Microarray Analysis (2021-2030) ($MN)
• Table 30 Europe Neurogenetic Testing Market Outlook, By Whole-Exome Sequencing (WES) (2021-2030) ($MN)
• Table 31 Europe Neurogenetic Testing Market Outlook, By Multiplex Ligation Dependent Probe Amplification (MLPA) (2021-2030) ($MN)
• Table 32 Europe Neurogenetic Testing Market Outlook, By Polymerase Chain Reaction (PCR) Tests (2021-2030) ($MN)
• Table 33 Europe Neurogenetic Testing Market Outlook, By Other Types (2021-2030) ($MN)
• Table 34 Europe Neurogenetic Testing Market Outlook, By End User (2021-2030) ($MN)
• Table 35 Europe Neurogenetic Testing Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 36 Europe Neurogenetic Testing Market Outlook, By Specialty Clinics (2021-2030) ($MN)
• Table 37 Europe Neurogenetic Testing Market Outlook, By Research Institutes (2021-2030) ($MN)
• Table 38 Europe Neurogenetic Testing Market Outlook, By Diagnostics Laboratories (2021-2030) ($MN)
• Table 39 Europe Neurogenetic Testing Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 40 Asia Pacific Neurogenetic Testing Market Outlook, By Country (2021-2030) ($MN)
• Table 41 Asia Pacific Neurogenetic Testing Market Outlook, By Type (2021-2030) ($MN)
• Table 42 Asia Pacific Neurogenetic Testing Market Outlook, By Microarray Analysis (2021-2030) ($MN)
• Table 43 Asia Pacific Neurogenetic Testing Market Outlook, By Whole-Exome Sequencing (WES) (2021-2030) ($MN)
• Table 44 Asia Pacific Neurogenetic Testing Market Outlook, By Multiplex Ligation Dependent Probe Amplification (MLPA) (2021-2030) ($MN)
• Table 45 Asia Pacific Neurogenetic Testing Market Outlook, By Polymerase Chain Reaction (PCR) Tests (2021-2030) ($MN)
• Table 46 Asia Pacific Neurogenetic Testing Market Outlook, By Other Types (2021-2030) ($MN)
• Table 47 Asia Pacific Neurogenetic Testing Market Outlook, By End User (2021-2030) ($MN)
• Table 48 Asia Pacific Neurogenetic Testing Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 49 Asia Pacific Neurogenetic Testing Market Outlook, By Specialty Clinics (2021-2030) ($MN)
• Table 50 Asia Pacific Neurogenetic Testing Market Outlook, By Research Institutes (2021-2030) ($MN)
• Table 51 Asia Pacific Neurogenetic Testing Market Outlook, By Diagnostics Laboratories (2021-2030) ($MN)
• Table 52 Asia Pacific Neurogenetic Testing Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 53 South America Neurogenetic Testing Market Outlook, By Country (2021-2030) ($MN)
• Table 54 South America Neurogenetic Testing Market Outlook, By Type (2021-2030) ($MN)
• Table 55 South America Neurogenetic Testing Market Outlook, By Microarray Analysis (2021-2030) ($MN)
• Table 56 South America Neurogenetic Testing Market Outlook, By Whole-Exome Sequencing (WES) (2021-2030) ($MN)
• Table 57 South America Neurogenetic Testing Market Outlook, By Multiplex Ligation Dependent Probe Amplification (MLPA) (2021-2030) ($MN)
• Table 58 South America Neurogenetic Testing Market Outlook, By Polymerase Chain Reaction (PCR) Tests (2021-2030) ($MN)
• Table 59 South America Neurogenetic Testing Market Outlook, By Other Types (2021-2030) ($MN)
• Table 60 South America Neurogenetic Testing Market Outlook, By End User (2021-2030) ($MN)
• Table 61 South America Neurogenetic Testing Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 62 South America Neurogenetic Testing Market Outlook, By Specialty Clinics (2021-2030) ($MN)
• Table 63 South America Neurogenetic Testing Market Outlook, By Research Institutes (2021-2030) ($MN)
• Table 64 South America Neurogenetic Testing Market Outlook, By Diagnostics Laboratories (2021-2030) ($MN)
• Table 65 South America Neurogenetic Testing Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 66 Middle East & Africa Neurogenetic Testing Market Outlook, By Country (2021-2030) ($MN)
• Table 67 Middle East & Africa Neurogenetic Testing Market Outlook, By Type (2021-2030) ($MN)
• Table 68 Middle East & Africa Neurogenetic Testing Market Outlook, By Microarray Analysis (2021-2030) ($MN)
• Table 69 Middle East & Africa Neurogenetic Testing Market Outlook, By Whole-Exome Sequencing (WES) (2021-2030) ($MN)
• Table 70 Middle East & Africa Neurogenetic Testing Market Outlook, By Multiplex Ligation Dependent Probe Amplification (MLPA) (2021-2030) ($MN)
• Table 71 Middle East & Africa Neurogenetic Testing Market Outlook, By Polymerase Chain Reaction (PCR) Tests (2021-2030) ($MN)
• Table 72 Middle East & Africa Neurogenetic Testing Market Outlook, By Other Types (2021-2030) ($MN)
• Table 73 Middle East & Africa Neurogenetic Testing Market Outlook, By End User (2021-2030) ($MN)
• Table 74 Middle East & Africa Neurogenetic Testing Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 75 Middle East & Africa Neurogenetic Testing Market Outlook, By Specialty Clinics (2021-2030) ($MN)
• Table 76 Middle East & Africa Neurogenetic Testing Market Outlook, By Research Institutes (2021-2030) ($MN)
• Table 77 Middle East & Africa Neurogenetic Testing Market Outlook, By Diagnostics Laboratories (2021-2030) ($MN)
• Table 78 Middle East & Africa Neurogenetic Testing Market Outlook, By Other End Users (2021-2030) ($MN)

According to Stratistics MRC, the Global Neurogenetic Testing Market is accounted for $616.7 million in 2023 and is expected to reach $1372.1 million by 2030 growing at a CAGR of 12.1% during the forecast period. Neurogenetic testing involves examining an individual's genetic makeup to identify specific genetic variations associated with neurological conditions. Its uses include diagnosing neurological disorders, assessing risk factors and guiding personalized treatment plans, leading to more targeted and effective healthcare interventions.

According to a WHO report, the European region contributes 11.2% of global burden of neurological disorder followed by Western Pacific region with 10%.

Market Dynamics:

Driver:

Rising prevalence of neurological disorders

The growing recognition and understanding of conditions like Alzheimer's, Parkinson's, and various neurodevelopmental disorders prompt a heightened demand for accurate and early genetic testing. Advances in neurogenetic testing provide a window into the genetic predispositions and risk factors for these conditions, facilitating early diagnosis and precise treatment planning. As these disorders gain prominence and medical understanding evolves, the need for effective neurogenetic testing becomes pivotal in tailoring interventions, enabling better management, and potentially averting or delaying the onset and progression of these challenging neurological conditions.

Restraint:

High costs associated with testing and limited accessibility

The complex nature of genetic testing methods, coupled with the need for specialized equipment and expertise, contributes to elevated testing costs, making these services unaffordable for many individuals. Additionally, limited accessibility to advanced neurogenetic tests, especially in underprivileged or remote regions, restricts the reach of these crucial diagnostic tools. As a result, disparities in access to cutting-edge healthcare solutions persist, preventing many from benefiting from early diagnosis, personalized treatment, and risk assessment for neurological conditions.

Opportunity:

Increasing research and development

Ongoing advancements in genetic testing technologies, coupled with deeper insights into the genetic underpinnings of neurological disorders, drive the development of more sophisticated, accurate, and comprehensive testing methods. This progress not only expands the scope of disorders that can be genetically tested but also enhances the precision and reliability of diagnostics. Moreover, it fuels the discovery of novel genetic markers and potential therapeutic targets, fostering the evolution of personalized medicine in neurology.

Threat:

The complexity of genetic testing methods

Genetic testing techniques, which often involve intricate processes like sequencing, microarray analysis, and interpretation of genetic variations, can be challenging to implement and comprehend. The need for highly specialized equipment, skilled professionals, and extensive bioinformatics analysis can lead to high operational costs, limiting accessibility to advanced testing. Additionally, the intricate nature of these tests may result in errors, data misinterpretation, or misdiagnoses, impacting their reliability and precision. Furthermore, the complexity of genetic testing can deter healthcare providers and patients from embracing these diagnostic tools, particularly in regions with limited technological infrastructure or healthcare expertise.

COVID-19 Impact:

The COVID-19 pandemic significantly impacted the market, driving both challenges and opportunities. While initial disruptions in supply chains and clinical operations affected testing accessibility, the urgency to understand neurological implications of the virus accelerated research and development in neurogenetics. Telehealth and remote testing gained prominence, facilitating patient access and diagnosis. This period underscored the importance of genetic testing in neurological disorders, prompting increased investment and innovation in testing technologies. Despite initial setbacks, the pandemic spurred advancements and a broader recognition of the critical role neurogenetic testing plays in healthcare, potentially reshaping the market's future landscape.

The polymerase chain reaction (PCR) tests segment is expected to be the largest during the forecast period

The polymerase chain reaction (PCR) test has a significant share in the market. PCR's ability to amplify DNA segments aids in detecting mutations linked to disorders like Huntington's disease or Parkinson's. Its high specificity and sensitivity empower accurate analysis of genetic markers, crucial in early diagnosis and disease monitoring. PCR's role extends to research, drug development, and personalized medicine within neurology, driving advancements in understanding the genetic basis of conditions. As a foundational tool, PCR tests continue to revolutionize neurogenetic testing, fostering insights that shape both research and clinical approaches.

The hospitals segment is expected to have the highest CAGR during the forecast period

The hospital has the highest CAGR within the market over the forecast period. They offer access to sophisticated testing facilities, allowing comprehensive genetic screenings, aiding in the identification of neurogenetic disorders. These institutions integrate testing into their diagnostic pathways, facilitating early disease detection and personalized treatment strategies. Hospitals also serve as centers for multidisciplinary collaboration, bringing together geneticists, neurologists, and other specialists to provide holistic care, contributing to ongoing research, and implementing cutting-edge testing methodologies, thereby significantly shaping the landscape of neurogenetic testing.

Region with largest share:

North America holds a significant position and expected to hold a largest share over the forecast period. The region houses leading biotech and pharmaceutical companies, fostering innovation and driving the development of cutting-edge testing methodologies. With a high prevalence of neurological disorders and a proactive healthcare system, North America witnesses extensive adoption of neurogenetic testing across clinical and research domains. The market in this region is characterized by a strong regulatory framework, strategic collaborations between academic institutions and industry, and a growing emphasis on personalized medicine, solidifying North America's position at the forefront of neurogenetic testing advancements.

Region with highest CAGR:

The Asia Pacific region witnessed highest CAGR in the market. With a large and diverse population, this region encounters a notable burden of neurological disorders, propelling the need for advanced diagnostic solutions. Furthermore, the presence of emerging economies and supportive government initiatives fosters collaborations between industry and research institutions, paving the way for expanded accessibility to testing and fueling the evolution of tailored approaches for diagnosing and managing neurological conditions in the Asia Pacific.

Key players in the market

Some of the key players in Neurogenetic Testing Market include: Invitae Corporation, Ambry Genetics, PerkinElmer, GeneDx, Centogene, Blueprint Genetics, Genomic Health (Exact Sciences), Fulgent Genetics, QIAGEN and Baylor Genetics.

Key Developments:

In April 2023, Ambry Genetics and LifeStrands Genomics had collaborated to provide clinical genetic testing services in Singapore. Together, they have been chosen to support the Clinical Implementation Pilots (CIPs) for Phase II of Singapore's National Precision Medicine (NPM) programme through an open tender commissioned by Precision Health Research, Singapore (PRECISE) - the central entity implementing NPM.

In April 2023, Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, announced that it will present new data highlighting the company's novel technology and approaches to early cancer detection at the American Association for Cancer Research® (AACR) Annual Meeting 2023 in Orlando, Florida.

In August 2022, PerkinElmer has signed an agreement with private equity firm New Mountain Capital for the sale of its Applied, Food and Enterprise Services businesses for $2.45bn in cash to allow the company to focus on its high-margin Life Science and Diagnostics businesses.

Types Covered:

• Microarray Analysis
• Whole-Exome Sequencing (WES)
• Multiplex Ligation Dependent Probe Amplification (MLPA)
• Polymerase Chain Reaction (PCR) Tests
• Other Types

End Users Covered:

• Hospitals
• Specialty Clinics
• Research Institutes
• Diagnostics Laboratories
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 End User Analysis
• 3.7 Emerging Markets
• 3.8 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Neurogenetic Testing Market, By Type

• 5.1 Introduction
• 5.2 Microarray Analysis
• 5.3 Whole-Exome Sequencing (WES)
• 5.4 Multiplex Ligation Dependent Probe Amplification (MLPA)
• 5.5 Polymerase Chain Reaction (PCR) Tests
• 5.6 Other Types

6 Global Neurogenetic Testing Market, By End User

• 6.1 Introduction
• 6.2 Hospitals
• 6.3 Specialty Clinics
• 6.4 Research Institutes
• 6.5 Diagnostics Laboratories
• 6.6 Other End Users

7 Global Neurogenetic Testing Market, By Geography

• 7.1 Introduction
• 7.2 North America
  • 7.2.1 US
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 UK
  • 7.3.3 Italy
  • 7.3.4 France
  • 7.3.5 Spain
  • 7.3.6 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 Japan
  • 7.4.2 China
  • 7.4.3 India
  • 7.4.4 Australia
  • 7.4.5 New Zealand
  • 7.4.6 South Korea
  • 7.4.7 Rest of Asia Pacific
• 7.5 South America
  • 7.5.1 Argentina
  • 7.5.2 Brazil
  • 7.5.3 Chile
  • 7.5.4 Rest of South America
• 7.6 Middle East & Africa
  • 7.6.1 Saudi Arabia
  • 7.6.2 UAE
  • 7.6.3 Qatar
  • 7.6.4 South Africa
  • 7.6.5 Rest of Middle East & Africa

8 Key Developments

• 8.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 8.2 Acquisitions & Mergers
• 8.3 New Product Launch
• 8.4 Expansions
• 8.5 Other Key Strategies

9 Company Profiling

• 9.1 Invitae Corporation
• 9.2 Ambry Genetics
• 9.3 PerkinElmer
• 9.4 GeneDx
• 9.5 Centogene
• 9.6 Blueprint Genetics
• 9.7 Genomic Health (Exact Sciences)
• 9.8 Fulgent Genetics
• 9.9 QIAGEN
• 9.10 Baylor Genetics